LSA
ALLO icon

L & S Advisors’s Allogene Therapeutics ALLO Stock Holding History

L & S Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,136
Closed -$777K – 297
2020
Q2 		$777K Buy
+18,136
New +$656K 0.12% 189

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

L & S Advisors's ALLO Position: Q3 2020 in Review

L & S Advisors sold out of Allogene Therapeutics (ALLO) in Q3 2020, closing a stake of 18,136 shares — an estimated $777K sold.

L & S Advisors first reported a position in ALLO in Q2 2020 and held it in 1 quarter. The position peaked at $777K in Q2 2020. 162 funds tracked by Wall St. Rank hold ALLO as of Q3 2020.

  • L & S Advisors reported no remaining Allogene Therapeutics position as of Q3 2020 after selling out during the quarter.
  • L & S Advisors sold 18,136 Allogene Therapeutics shares in Q3 2020, an estimated $777K.
  • L & S Advisors first reported a position in Allogene Therapeutics in Q2 2020 and held it in 1 quarter.
  • L & S Advisors's Allogene Therapeutics position peaked at $777K in Q2 2020.
  • 162 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2020.

Based on L & S Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.